Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) insider Ngai Hang Victor Chong acquired 36,500 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $1.00 per share, with a total value of $36,500.00. Following the acquisition, the insider now directly owns 100,000 shares in the company, valued at $100,000. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
Clearside Biomedical Price Performance
Shares of Clearside Biomedical stock opened at $1.07 on Wednesday. The business has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $1.20. Clearside Biomedical, Inc. has a 1 year low of $0.76 and a 1 year high of $2.12. The company has a market capitalization of $79.96 million, a price-to-earnings ratio of -2.14 and a beta of 2.33.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.25 million. During the same quarter in the prior year, the business posted ($0.15) EPS. As a group, equities analysts anticipate that Clearside Biomedical, Inc. will post -0.56 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Clearside Biomedical
Analysts Set New Price Targets
CLSD has been the subject of a number of analyst reports. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Monday, October 14th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 27th. StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Friday, October 18th. Finally, Needham & Company LLC lifted their price objective on shares of Clearside Biomedical from $4.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Clearside Biomedical presently has a consensus rating of “Moderate Buy” and an average target price of $5.17.
View Our Latest Stock Analysis on Clearside Biomedical
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
- Five stocks we like better than Clearside Biomedical
- How to Use the MarketBeat Excel Dividend Calculator
- Palantir Cracks $50, Is There Still Time to Get on Board?
- 3 Warren Buffett Stocks to Buy Now
- Insider Buying Signals Upside for These 3 Stocks
- Energy and Oil Stocks Explained
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.